Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 2 of 4: Calculated dose-response metrics. - Dataset (ID:20269)
Download: Excel (XLSX), Comma-separated (CSV)
Cell | Clinical Subtype | Transcriptional Subtype | Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | Biological Replicate ID | Conc Unit | GR50 | GEC50 | GRmax | GRinf | GR Hill Coefficient | GR_AOC | GR r2 | Nominal Division Rate |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
MDA-MB-361 | HER2amp | Luminal | Trastuzumab | HER2 | ErbB | 9648.026 | uM | inf | 0.00320 | 0.3886 | 0.5402 | 1.5326 | 0.2764 | 0.8808 | 0.7065 | |
MDA-MB-453 | TNBC | Luminal | Trastuzumab | HER2 | ErbB | 9723.124 | uM | inf | 0.00115 | 0.4864 | 0.6553 | 4.9994 | 0.2269 | 0.8119 | 0.9827 | |
SK-BR-3 | HER2amp | Luminal | Trastuzumab | HER2 | ErbB | 10127.123 | uM | inf | inf | 0.2747 | 0.2747 | 0.0000 | 0.4731 | 0.1249 | 0.8767 | |
SUM102PT | TNBC | Basal B | Trastuzumab | HER2 | ErbB | 9777.124 | uM | inf | inf | 0.8331 | 0.8331 | 0.0000 | 0.0175 | 0.2896 | 0.6278 | |
SUM185PE | TNBC | Luminal | Trastuzumab | HER2 | ErbB | 10146.124 | uM | inf | inf | 0.8709 | 0.8709 | 0.0000 | -0.0388 | 0.2980 | 0.9296 | |
184A1 | NM | Basal | Trastuzumab | HER2 | ErbB | 9047.026 | uM | inf | inf | 0.2837 | 0.2837 | 0.0000 | 0.2170 | 0.0804 | 0.5972 | |
184B5 | NM | Basal | Trastuzumab | HER2 | ErbB | 9095.026 | uM | inf | 6.71320 | 0.7144 | 0.5130 | 4.9565 | -0.0290 | 0.80 | 1.0168 | |
CAMA-1 | HR+ | Luminal | Trastuzumab | HER2 | ErbB | 9210.026 | uM | inf | inf | 0.9536 | 0.9536 | 0.0000 | -0.0426 | -1.3374 | 0.9102 | |
HCC1395 | TNBC | Basal B | Trastuzumab | HER2 | ErbB | 9254.124 | uM | inf | inf | 0.8784 | 0.8784 | 0.0000 | -0.0335 | 0.3867 | 0.8067 | |
HCC1428 | HR+ | Luminal | Trastuzumab | HER2 | ErbB | 7441.102 | uM | inf | inf | 0.9313 | 0.9313 | 0.0000 | -0.0087 | 0.3093 | 0.9144 | |
HCC1569 | HER2amp | Basal A | Trastuzumab | HER2 | ErbB | 7447.102 | uM | inf | 0.00181 | 0.7277 | 0.8106 | 1.1886 | 0.1183 | 0.8186 | 1.6467 | |
HCC1569 | HER2amp | Basal A | Trastuzumab | HER2 | ErbB | 9347.026 | uM | inf | inf | 0.7097 | 0.7097 | 0.0000 | 0.0656 | 0.4960 | 1.2965 | |
AU565 | HER2amp | Luminal | Trastuzumab | HER2 | ErbB | 9146.122 | uM | inf | 0.00184 | 0.5003 | 0.6442 | 5.0000 | 0.2137 | 0.8848 | 1.3408 | |
HCC1954 | HER2amp | Basal A | Trastuzumab | HER2 | ErbB | 9386.026 | uM | inf | inf | 0.7531 | 0.7531 | 0.0000 | 0.0956 | 0.4287 | 1.5583 | |
HCC38 | TNBC | Basal B | Trastuzumab | HER2 | ErbB | 9469.026 | uM | inf | inf | 0.8380 | 0.8380 | 0.0000 | 0.0264 | 0.4874 | 1.2092 | |
BT-474 | HER2amp | Luminal | Trastuzumab | HER2 | ErbB | 9158.123 | uM | 0.01277 | 0.00885 | -0.0100 | 0.0993 | 0.6043 | 0.4533 | 0.9046 | 0.8769 | |
HBL-100 | Unknown | Unknown | Pertuzumab | 7429.102 | mg/ml | inf | 0.21142 | 0.9391 | 0.9176 | 0.6095 | 0.0085 | 0.7039 | 2.4347 | |||
MCF 10F | NM | - | Pertuzumab | 7487.102 | mg/ml | inf | 124.94960 | 0.6533 | -0.1750 | 0.2135 | 0.1284 | 0.7894 | 1.5273 | |||
MCF12A | NM | Basal B | Pertuzumab | 7489.102 | mg/ml | inf | 125.00000 | 0.8728 | 0.5007 | 0.2455 | 0.0447 | 0.7417 | 2.4234 | |||
HCC1569 | HER2amp | Basal A | Pertuzumab | 7447.102 | mg/ml | inf | 124.99960 | 0.8861 | 0.6968 | 0.1346 | 0.0581 | 0.6369 | 1.6467 | |||
HCC1428 | HR+ | Luminal | Pertuzumab | 7441.102 | mg/ml | inf | inf | 0.9063 | 0.9063 | 0.0000 | 0.0249 | 0.2346 | 0.9144 | |||
BT-20 | TNBC | Basal A | Pertuzumab | 5903.102 | mg/ml | inf | inf | 0.9324 | 0.9324 | 0.0000 | -0.0074 | -0.0405 | 1.2557 | |||
HCC1395 | TNBC | Basal B | Cetuximab | EGFR | ErbB | 7813.018 | uM | 0.82620 | 0.82952 | 0.7195 | -0.0101 | 4.9982 | 0.0073 | 0.6447 | 0.8420 | |
HCC1395 | TNBC | Basal B | Cetuximab | EGFR | ErbB | 9258.026 | uM | inf | inf | 0.7953 | 0.7953 | 0.0000 | 0.0354 | 0.3593 | 0.5632 | |
HCC1395 | TNBC | Basal B | Cetuximab | EGFR | ErbB | 9254.124 | uM | 1.07170 | 0.71327 | 0.7439 | 0.4322 | 4.9081 | -0.0186 | 0.7673 | 0.8067 |